Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00522990
• Other study ID #: AT9283/0002
• Secondary ID: 2006-0177
• Status: Terminated
• Phase: Phase 1/Phase 2
• First received: August 29, 2007
• Last updated: January 8, 2016
• Start date: September 2006
• Est. completion date: April 2009

Study information

• Verified date: January 2016
• Source: Astex Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia. Researchers want to perform pharmacokinetic (PK) testing on blood to find out how quickly the study drug leaves the body and how the body breaks down the drug. The safety and effectiveness of this drug will also be studied.

Description:

Dose escalation study of AT9283 administered to patients with refractory hematological malignancies. Study objectives include identification of MTD and dose limiting toxicities, preliminary assessment of efficacy and definition of pharmacokinetic profile

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 48
• Est. completion date: April 2009
• Est. primary completion date: April 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of signed written informed consent

2. Histological or cytological confirmation of one of the following:

Relapsed or refractory AML or ALL; acute leukaemia in patients who are unsuitable for or refuse standard therapy

CML in chronic phase, accelerated phase or blast crisis that is resistant or refractory to standard therapy

High-risk MDS, defined as the presence of:

i)Refractory anemia with excess blasts (RAEB, 5-19% bone marrow blasts)

or

ii)RAEB in transformation to AML (RAEBT with 20-30% bone marrow blasts)

Advanced MMM defined by the presence of one or more of the following features:

i)Hemoglobin < 10 gm/dL (100 g/L)

ii)Platelet count < 100 x 109/L

iii)White blood cell count < 4 x 109/L

iv)Symptomatic splenomegaly or other disease-related symptoms inadequately controlled by conventional therapies

3. ECOG performance status 0, 1 or 2

4. Male or female, age 18 years or older

5. Negative pregnancy test or history of surgical sterility or evidence of post-menopausal status (post-menopausal status is defined as any of the following: natural menopause with menses >1 year ago; radiation induced oophorectomy with last menses >1 year ago; chemotherapy induced menopause with 1 year interval since last menses

Exclusion Criteria:

1. Inadequate liver function as demonstrated by serum bilirubin =1.5 times the upper limits of reference range (ULRR) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or alkaline phosphatase (ALP) =2.5 times the ULRR (or =5 times the ULRR in the presence of liver metastases)

2. Impaired renal function as demonstrated either by an isolated creatinine value of =1.5 times the ULRR OR creatinine clearance < 50 mL/min determined by Cockcroft-Gault formula. Note there is no requirement to determine a formal creatinine clearance if the patient's serum creatinine value is =1.5 times the ULRR.

3. Radiotherapy or chemotherapy within the 14 days prior to the first dose of AT9283 being administered (Day 1, dose level 1). Planned use of hydroxyurea other than as is permitted as described in section 11.9.

4. Receiving an investigational anti-cancer treatment concurrently or within 14 days prior to the start of AT9283 infusion (Day 1)

5. Unresolved CTCAE grade 2 or greater toxicity (other than stable toxicity) from previous anti-cancer therapy excluding alopecia

6. Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol

7. Active, uncontrolled central nervous system disease

8. Ischemic heart disease or myocardial infarction or unstable cardiac disease within 3 months of study entry

9. Prior infection with human immunodeficiency virus (HIV), hepatitis B or C viruses - screening for viral infections is not required for entry to this study

10. Major surgery within 28 days prior to the start of AT9283 infusion (Day 1) - excluding skin biopsies and procedures for insertion of central venous access devices

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Myelofibrosis
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Preleukemia

Intervention

Drug:
• AT9283
Three weekly intravenous administration of AT9283

Locations

Country	Name	City	State
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	The University of Texas, MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Astex Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (1)

Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability		Up to 30 days after completing therapy with AT9283	Yes
Secondary	Pharmacokinetic profile, Safety and tolerability of maximum tolerated dose, efficacy, pharmacodynamic effect, identify dose limiting toxicities		Within six months of initiating therapy with AT92823	Yes

External Links

•   Publication of the Study Results